Pharm Aid Ltd – Leading the Way

Pharm Aid is a future-forward pharmaceutical company set to become the leading regional research and development hub and a significant producer of multiple novel vaccines and immuno-biopharmaceutical therapies in Russia and CIS, offering full-cycle technology.

We are building the country’s first live virus manufacturing line with a range of best-in-class products developed both in-house and with our international partners, focusing on innovative combined immunobiological drugs to prevent and treat significant diseases.

Within our bespoke, high-tech facility, our research and development

department combines the best practices available from Russian and global biotechnology companies to increase the accessibility of quality treatments for Russian patients.

As such, we will offer the country its first and largest full-cycle, fully integrated recombinant, live and inactivated viral and bacterial vaccine and antibody research, development and  manufacturing facility. This modern biopharmaceutical complex will produce a wide range of innovatory multi-component products developed and  manufactured in the country via superior technology and IP inlicensed from our pioneering partners.

OUR VISION

We’re focused on helping and protecting communities across Russia and the CIS by providing affordable, high quality healthcare and making best-in-class global standard biopharmaceutical treatment options available to all. In doing so, we will contribute to the  development and modernization of the
national pharmaceutical industry in Russia in accordance with the Russian Federation’s strategy to achieve independence from the import of essential drugs.

We understand that good health can’t wait, which is why we provide increased market access to contemporary, cutting-edge immunobiological drugs and therapy options at an affordable price. In doing so, federal budgets and out-of-pocket patient expenses can be allocated elsewhere, helping to ensure universal coverage. This overarching purpose precedes our motives for profits.

Collaborating for a better future

Pharm Aid Ltd. was established on May 26, 2017, as a joint venture between Rostec State Corporation and Ishvan Pharmaceuticals Ltd. Our mission has been made possible thanks to international collaboration and knowledge sharing with leading pharmaceutical companies in the areas of vaccine technology transfer, manufacturing, and commercialization. Achieving it will ensure the sustainable development and modernization of the national pharmaceutical industry to produce new, affordable drugs domestically, resulting in significant financial savings for the Federal healthcare budget.

INTERNATIONAL

COLLABORATION

RESEARCH

& DEVELOPMENT

FULL-CYCLE

MANUFACTURING

NEW LOCALLY –

PRODUCED DRUGS

INNOVATIVE, EFFECTIVE, AND AFFORDABLE PRODUCTS
We aim to create full-cycle local development and manufacturing operations for the following vaccines and immunobiological  preparations:
  • Varicella Vaccine
  • Rotavirus Vaccine
  • Human Papillomavirus Vaccine
  • Meningococcal Vaccine
  • Monoclonal Antibody for Rabies
  • MMR Vaccine (Measles, Mumps, Rubella)
KEY OBJECTIVES
Our key objectives are:
  • Secure best-in-class technology for new, innovative vaccines and  immunobiological product pipeline creation.
  • Development of a state-of-the-art R&D center and manufacturing plant supported by  technology transfer to achieve full-cycle localized production of immunobiological drugs and vaccines in Russia.
  • Increase market access to effective and affordable therapies for Russian patients.

CUTTING-EDGE INFRASTRUCTURE

Our biopharmaceutical complex is being built across 50,000 sqm in Kaluga’s Special Economic Zone, following stringent BSL-3/4 (WHO: BSL-1/2) regulations. Situated in Vorsino Industrial Park in the Kaluga region, close to renowned pharmaceutical giants, such as Astra Zeneca, it will feature three integrated sites, each equipped with ultra-high-speed, European-standard production lines, which have the capacity to fulfill Russia and the Eurasian Union’s national immunization  requirements. With a multi-campaign mode smart design concept, each versatile production site will have the flexibility to produce more than one vaccine, facilitating the faster production scale-up of a large number of doses to respond to any national emergency or outbreak situation.

H

The state-of-the-art manufacturing plants will have sophisticated tunnel systems, high-speed vial washing, filling, stoppering, lyophilisation and sealing machines capable of  working at an integrated  and fully-automated speed  of 500 containers per  minute, installed with a filling accuracy to the third digit of decimal point to ensure accuracy and  consistency. These plants will utilize bio isolators with the highest sterility assurance levels and be capable of handling comprehensive viral antigen production on-site in accordance with cGMP and European regulatory requirements.

Our research and development center is planned to be equipped withstate-of-the-art antigen production and conjugation, purification, characterization and  formulation development technologies for recombinant, vector-based mRNA, as well as live attenuated and inactivated viral and bacterial vaccines and antibodies.

Our quality control laboratory will be equipped with the latest sophisticated, high-tech equipment and instruments on computerized systems that will ensure the comprehensive testing of antigens, drug substances and finished products for their characteristics, purity, consistency and accuracy along the entire production cycle.

The biopharmaceutical complex, built under technology collaboration with our industry-leading partners, will be compliant to cGMP, ISO, European quality management systems and approved by Russian, Eurasian, and international regulatory authorities.

FEATURES

MORE INFORMATION

If you would like more information or would like to speak to us about specific areas of cooperation, then please fill in the form below and one of our senior managers will contact you directly.